To assess how well MVS-A would perform in a real drug discovery campaign, we investigated whether the true actives identified by our method have satisfactory selectivity and ADME properties, making them suitable for further clinical testing. To do so, we reevaluated the dataset with codename "transporter" from the publicly available HTS assays evaluated in this work. This assay was conducted in order to identify novel inhibitors for the presynaptic choline transporter (CHT), a potential therapeutic target for Alzheimer's disease and schizophrenia. We chose this dataset from our collection as a case study because the hits from its primary HTS screen were extensively validated by 9 additional counterscreens and confirmatory assays (PubChem AID 488997). The goal of these analyses was to identify potent, selective CHT inhibitors eliciting the desired phenotypic response from primary HTS hits.